Overview

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Status:
Completed

Trial end date:
2018-06-22

Target enrollment:

Participant gender:

Summary

This study is designed as an open-label randomized parallel two-arm multicenter efficacy, pharmacokinetics and safety study of intravenously administered eribulin versus intravenously administered vinorelbine in Chinese population. Eligible female subjects will have measurable disease according to RECIST 1.1 with the modification that chest x-ray cannot be used for assessment of disease.

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Taxane
Vinblastine
Vinorelbine